Section Arrow
EDIT.NASDAQ
- Editas Medicine
Quotes are at least 15-min delayed:2026/04/18 03:05 EDT
Regular Hours
Last
 3.49
+0.14 (+4.18%)
Day High 
3.555 
Prev. Close
3.35 
1-M High
3.575 
Volume 
1.64M 
Bid
3.42
Ask
3.48
Day Low
3.36 
Open
3.4 
1-M Low
2.13 
Market Cap 
327.87M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA
20-SMA 2.68 
50-SMA 2.31 
52-W High 4.5372 
52-W Low 1.23 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.80/-1.13
Enterprise Value
339.94M
Balance Sheet
Book Value Per Share
0.28
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
40.52M
Operating Revenue Per Share
0.25
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TOVXTheriva Biologics Inc0.2572+0.0049+1.94%0.09PE
PBMPsyence Biomedical Ltd.7.6+1.73+29.47%-- 
GERNGeron Corp1.68-0.01-0.59%-- 
IBRXImmunityBio7.7+0.45+6.21%-- 
ADMAADMA Biologics11.01+0.27+2.51%17.92PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.